Pharma is an unusually transparent industry for competitive intelligence. Clinical trials have to be registered publicly. Regulators publish their decisions. Companies disclose material developments to investors. Congresses publish their programs months in advance. A competitor’s next move is often visible a year or more before it happens, to anyone who is paying attention in the right places.
That transparency is also the challenge. There is far more public information than any team can follow by hand, and the signal that matters is mixed with a great deal that does not. Good pharma CI is less about finding secrets and more about seeing clearly, early, and in context.
This guide covers what competitive intelligence means in pharma, what to track, how to turn a stream of events into decisions, where the ethical lines sit, and how to organize the work.
What makes competitive intelligence different in pharma
Some features of the industry shape almost everything a pharma CI team does.
Long, visible timelines. A drug takes years to reach the market, and most of the milestones along the way are public. Trial registrations show what is being tested, in whom, and roughly when results are expected. That makes pharma CI unusually predictive. The question is rarely whether a competitor is coming. It is when, with what data, and with what label.
Regulated disclosure. In the United States and the European Union, most interventional trials must be registered publicly, and results must be posted within set timelines. Regulators publish approvals, label text and safety communications. Listed companies must disclose material events to investors. A great deal of competitive information is therefore not only public but structured.
Binary events. Many of the events that matter are yes-or-no: a trial meets its primary endpoint or it does not, a regulator approves or issues a complete response letter, a patent holds or falls. CI teams spend much of their time preparing for both outcomes.
Access shapes everything. In pharma, a competitor’s success depends not only on its data but on how payers cover it. Formulary decisions, prior authorization criteria and health technology assessments are as much a part of the competitive picture as efficacy.
The exclusivity cliff. Every product eventually faces loss of exclusivity. The timing of generic or biosimilar entry, for your brand and your competitors, is one of the most consequential facts a CI team tracks.
Competitive intelligence, market intelligence and market research
These terms are used loosely, and many companies combine the functions. The distinctions are still useful when deciding who does what.
| What differs | Competitive intelligence | Market intelligence | Market research |
|---|---|---|---|
| Focus | Specific competitors and what they will do | The market as a whole: size, growth, structure, trends | What customers think and do |
| Typical question | What will Company X do after its readout, and how should we respond? | How fast is this market growing, and where is growth coming from? | Why do physicians choose one product over another? |
| Main inputs | Trials, regulatory events, labels, patents, deals, company disclosures, congress data | Epidemiology, prescription and sales data, forecasts, policy | Surveys, interviews, panels, prescribing data |
| Typical outputs | Competitor profiles, scenarios, catalyst calendars, war games | Market models, forecasts, segment analyses | Segmentation, message testing, attitude and usage studies |
Medical intelligence overlaps with all three, but serves the medical organization and stays on the non-promotional side of the line. Our guide to medical intelligence covers that side in detail.
What to track
The table below lists the event types most pharma CI programs follow, why each matters, and how much warning a team usually gets.
| Event | Why it matters | Typical warning |
|---|---|---|
| New trial registration | Shows what a competitor is testing, in whom, against what, and when results may come | Years |
| Trial status change | Enrollment completed, terminated, suspended or results posted | Weeks to months |
| Data readout | Topline results, often by press release, then full data at a congress | Months, from the registry and company guidance |
| Congress presentation | Full data, subgroup analyses and the first expert reaction | Weeks, from published programs |
| Regulatory submission | Starts the clock on a decision | Months, from company guidance |
| PDUFA date or EU decision | The expected date of a regulatory decision | Usually disclosed at submission or acceptance |
| Advisory committee meeting | A public discussion that often signals the regulator’s concerns | Weeks, from published notices |
| Approval and label | Defines what a competitor can claim and for whom | The label text is the key detail, often only known on approval |
| Safety communication or label change | Can shift prescribing quickly | Often little or none |
| Pricing and coverage decision | Determines how many patients can actually get the product | Varies; often visible only after it takes effect |
| HTA decision | Shapes access outside the US | Months, from published assessment timelines |
| Patent challenge or expiry | Sets the timing of generic or biosimilar entry | Years, with uncertainty from litigation |
| Deal, licensing or acquisition | Changes who owns an asset and how well it is funded | Usually none |
| Guideline update | Changes how clinicians are told to treat the condition | Months, if the guideline body publishes its process |
The most useful CI programs follow all of these for a defined set of competitors and products, rather than a few of them for everyone.
The catalyst calendar
A catalyst calendar puts the dated events from the table above on a single timeline, usually twelve to twenty-four months ahead. It is one of the simplest tools in CI and one of the most valuable.
Its power is that it lets the rest of the organization plan around events instead of reacting to them. If a competitor’s regulatory decision is expected in the second quarter of next year, the brand plan, the medical plan, the access strategy and the forecast can all account for it now. Scenarios for approval and for rejection can be prepared in advance.
A few practices make a catalyst calendar trustworthy:
- Every date has a source. A company press release, an investor presentation, a regulator’s notice or a registry entry. If the date came from a broker note or a blog, say so, and treat it as softer.
- Precision is explicit. “March 14” and “the first half of next year” are different kinds of information. Show which is which.
- Dates are re-checked. Timelines slip. Submissions are delayed, reviews are extended, readouts move. A calendar that is not re-checked monthly becomes misleading quickly.
- Implications are attached. For the events that matter most, note what each outcome would mean for your brand.
Competitor profiles and the competitor matrix
The second core tool is a structured comparison of your product and its competitors. Most teams keep this as a matrix, with products across the top and attributes down the side.
A good matrix covers, for each product, the approved indications and line of therapy, the mechanism, the pivotal evidence and its headline results, dosing and administration, the main safety considerations, the approval dates in each market, the list price and coverage position, the exclusivity timeline, and what is coming next. It also records when each cell was last checked and where the information came from.
We publish a free competitor matrix template with this structure, which is a reasonable starting point for a single brand. The limitation of any spreadsheet is upkeep. A matrix that is updated quarterly is wrong for most of the quarter.
From events to implications
Collecting information is the easy part. The value of CI is in the answer to “so what?”
A useful discipline is to write three things for every significant event:
- What happened, in one or two factual sentences, with the source.
- Why it matters to us, specifically. Not “this increases competition,” but “if approved with this label, the competitor will be the only option in second line for patients with this marker, which is roughly a fifth of our current share.”
- What we should consider doing, or what we should watch next, with a date.
This format forces the analysis that stakeholders actually want, and keeps briefings short. Leadership rarely needs ten pages on a competitor’s readout. They need to know whether to change anything.
For bigger questions, two structured methods are widely used:
- Scenario planning. For an uncertain event, such as a competitor’s approval, describe two or three plausible outcomes, what would signal each one, and how the company would respond. Prepare the responses before the event.
- War gaming. Teams role-play competitors, payers and the company itself to test a strategy against realistic reactions. War games are most useful before a launch or a major competitor event, and they expose assumptions that a slide deck would hide.
The ethical and legal lines
Competitive intelligence is a legitimate and well-established discipline, and almost everything a pharma CI team needs is public. The lines are clear, and a CI program should make them explicit.
Use public information and legitimate research. Publications, registries, regulatory documents, company disclosures, congress presentations, patent filings and properly conducted primary research are all fair game.
Never misrepresent who you are. Interviewers must not pose as students, journalists or potential customers to obtain information. If a research agency is used, it must follow the same rule.
Never seek confidential information. That includes information covered by a confidentiality agreement, information from a competitor’s current or former employees that they are obliged to protect, and anything obtained through improper means.
Be careful with competitors directly. Exchanging competitively sensitive information with a competitor, such as pricing, bids or strategy, raises antitrust concerns. Legal should review any direct contact.
Report adverse events. If primary research commissioned by a pharma company turns up a possible adverse event involving one of its products, it usually has to be passed to drug safety. Industry market research codes build this into their standards, and agencies should be briefed on it.
The code of ethics published by SCIP, the main professional association for competitive intelligence, is widely used as a reference, and many companies adopt it as their own policy.
Organizing the CI function
There is no single right structure, but most pharma companies use one of three.
Central CI team. A dedicated group serves the whole company, often from strategy or commercial excellence. It builds deep expertise and avoids duplication, but can feel distant from individual brands.
Embedded analysts. CI analysts sit within franchises or brand teams. They are close to the decisions, but may duplicate each other’s monitoring and lose sight of cross-portfolio patterns.
Hub and spoke. A small central team owns the monitoring, the tools and the standards, and embedded analysts do the brand-specific analysis. This is increasingly common, because it puts the routine work in one place and the judgment close to the decisions.
Whatever the structure, a few practices separate effective CI teams from busy ones:
- A defined scope of competitors and products, reviewed when the portfolio changes.
- A clear cadence: same-day alerts for major events, a weekly summary of what changed, a deeper quarterly review.
- Named stakeholders for each output, with a sense of what decisions each one makes.
- A habit of asking afterwards whether the intelligence arrived in time to matter.
Build, buy or outsource
CI teams have three broad options for the monitoring work.
Build it in-house. Analysts monitor sources directly using general tools and spreadsheets. This is flexible and cheap to start, but it scales poorly and depends heavily on individuals.
Use an agency. Specialist agencies provide monitoring, reports and primary research. This works well for defined projects and for primary research, which an internal team usually should not run itself. It is harder to make it a continuous, shared picture.
Use a platform. Software keeps the competitive picture current and shared, and frees analysts for interpretation. It works best when it is set up around the company’s own competitors and questions rather than a generic view of the industry.
Most mature programs combine all three: a platform for continuous monitoring, agencies for primary research and special projects, and an internal team for judgment.
Measuring CI impact
CI is notoriously hard to measure, but a few questions get close.
- How often did a significant competitor event surprise the people it affected?
- How long after an event did the right people hear about it?
- Which decisions in the last quarter did CI inform, and what would have happened otherwise?
- Are the outputs being read and used, or filed?
The first two are the most honest. A CI function that rarely gets surprised, and that tells people quickly when something happens, is doing its job.
Further reading
- The FDA’s page on PDUFA explains the user fee program behind regulatory review timelines.
- The FDA’s frequently asked questions on patents and exclusivity covers how exclusivity periods work in the US.
- ClinicalTrials.gov is the main public registry for trials run in the United States and many elsewhere.
- Our glossary defines the regulatory and market access terms used in this guide.